Last update: Dec. 4, 2020
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
A glutamate antagonist, indicated in the treatment of amyotrophic lateral sclerosis.
Oral administration in two daily doses.
Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) explain the very low transfer into breastmilk observed.
In addition, absorption decreases with fatty foods, so that the little amount that does reach breastmilk will be less absorbed by the infant.
Until there is more published data on this drug in relation to breastfeeding, known safer alternatives during the neonatal period and in the event of prematurity may be preferable.
We do not have alternatives for Riluzole.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM